Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:18:50 EDT Tue 01 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:GILD
- GILEAD SCIENCES INC -
https://www.gilead.com
00:18:50 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
GILD
- Q
0.1
110.16
·
111.36
9.0
110.87
+0.20
0.2
6,600.5
727,949
51,808
110.61
111.44
109.88
119.95 66.01
19:52:11
Jun 25
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 51808
More trades...
Time ET
Ex
Price
Change
Volume
19:52:11
Q
111.23
0.56
54
19:52:11
Q
111.25
0.58
400
19:51:00
Q
111.23
0.56
36
19:49:21
Q
111.2006
0.5306
4
19:49:16
Q
111.12
0.45
6
19:49:16
Q
111.20
0.53
100
19:49:16
Q
111.20
0.53
99
19:48:52
Q
111.18
0.51
90
19:48:52
Q
111.20
0.53
750
19:43:34
Q
111.17
0.50
36
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-06-25 07:00
U:GILD
News Release
200
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
2025-06-24 09:25
U:GILD
News Release
200
Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion
2025-06-18 14:49
U:GILD
News Release
200
Yeztugo(TM) (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
2025-06-05 09:20
U:GILD
News Release
200
Gilead Sciences: Advancing New Ways To Help End the HIV Epidemic Is the Focus of This Installment of "The Centrifuge Sessions"
2025-06-01 08:00
U:GILD
News Release
200
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta(TM) in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
2025-05-31 08:00
U:GILD
News Release
200
Trodelvy(TM) Plus Keytruda(TM) Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
2025-05-30 09:35
U:GILD
News Release
200
Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden
2025-05-23 08:30
U:GILD
News Release
200
ASCENT-03: Trodelvy(TM) Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
2025-05-20 09:02
U:GILD
News Release
200
Tomas Cihlar, Gilead Sciences, Named to TIME's List of 100 Most Influential People in the World for HIV Research
2025-05-15 16:15
U:GILD
News Release
200
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
2025-05-15 09:27
U:GILD
News Release
200
Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories
2025-05-13 08:51
U:GILD
News Release
200
The 2024 Responsible Business and Impact Report Shares How Gilead Sciences Is Driving Change
2025-05-08 09:02
U:GILD
News Release
200
Earth Day Focus for Gilead Sciences - Every Action Has an Impact
2025-05-07 02:30
U:GILD
News Release
200
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
2025-05-07 02:15
U:GILD
News Release
200
Gilead's Livdelzi(TM) (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
2025-05-06 08:41
U:GILD
News Release
200
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"
2025-04-29 16:05
U:GILD
News Release
200
Gilead Sciences to Present at Upcoming Investor Conferences
2025-04-29 08:36
U:GILD
News Release
200
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV's Impact in the United States
2025-04-29 08:30
U:GILD
News Release
200
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
2025-04-24 16:02
U:GILD
News Release
200
Gilead Sciences Announces First Quarter 2025 Financial Results